DeepLife
Jonathan Baptista is a seasoned professional in the fields of engineering and entrepreneurship, currently serving as Co-founder and CEO of DeepLife since August 2019, focusing on AI-augmented cell engineering for drug discovery. Prior to this, Jonathan founded and led GinGo, promoting fair and open science from October 2017 to December 2020. Jonathan's engineering management experience includes a role as Robotics R&D Manager at Safran Electronics & Defense, where proficiently ensured technical feasibility of powered exoskeletons, as well as contributions as Advanced Sealing Technologies R&D Program Coordinator and Project Engineer, focusing on mechanical seals for aerospace applications. Earlier in Jonathan's career, experience was gained as a 4D Finite Elements programmer at McGill University's Vibrations and Structural Dynamics Laboratory and as a welding process engineer at Snecma. Jonathan's educational background includes a Master's degree in Dynamics of Structures, Materials, and Coupled Systems from CentraleSupélec and a Master's degree from Mays Business School at Texas A&M University.
This person is not in any teams
DeepLife
DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.